Clarithromycin (Biaxin®) extended-release tablet: A therapeutic review

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 9-20

  Gotfried, Mark H ^a  

^a Pulmonary Associates   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Clarithromycin extended release; Community acquired pneumonia; Sinusitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ASTEMIZOLE; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PENICILLIN V; PIMOZIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERFENADINE; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN; ANTIINFECTIVE AGENT;

ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; GASTROINTESTINAL ABSORPTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEARING LOSS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MAXILLA SINUSITIS; MYCOBACTERIUM AVIUM; NAUSEA; NEUTROPENIA; POSTMARKETING SURVEILLANCE; PSEUDOMEMBRANOUS COLITIS; QT PROLONGATION; REVIEW; SMELLING DISORDER; STEVENS JOHNSON SYNDROME; TABLET; TASTE DISORDER; THROMBOCYTOPENIA; TOOTH COLOR; TOOTH DISEASE; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; BRONCHITIS; COMMUNICABLE DISEASE; DELAYED RELEASE FORMULATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHITIS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DELAYED-ACTION PREPARATIONS; HUMANS; TABLETS;

EID: 85047691294     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.9     Document Type: Review

References (56)

1. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann. Pharmacother. 27(9 Suppl.), S1-24 (1993).
2. Branthwaite A, Pechere JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J. Int. Med. Res. 24(3), 229-238 (1996).
3. Notario G, Takker U, Dzyublyk O et al. Comparison of five days of extended-release clarithromycin versus ten days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: Results of a multicenter, double-blind, randomized study. Curr. Med. Res. Opin. (In Press).
4. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin and azithromycin. Mayo Clin. Proc. 74, 613-634 (1999).
5. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharmacokinet. 11, 137-152 (1992).
6. Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann. Pharmacother, 26, 1099-1108 (1992).
7. Guay DR, Gustavson LE, Devcich KJ et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23, 566-577 (2001).
8. Mazzei T, Mini E, Novelli A et al. Chemistry and mode of action of macrolides. J. Antimicrob. Chemother. 31(Suppl. C), 1-9 (1993).
9. Steigbigel NH. Macrolides and clindamycin. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases (5th Edition). Churchill Livingstone, PA, USA, 366-382 (2000).
10. Abbott Laboratories. Biaxin® XL Filmtab®: (clarithromycin extended release tablets). Precribing information (online). Available from www.rxabbott.com/bx/xl/bxx006.htm. 2002 June
11. Felmingham D. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms. J. Antimicrob. Chemother. 45(Topic T2), 1-8 (2000).
12. Mandell's Principles and Practice of Infectious Diseases (5th Edition). 1(27), 367 (2002).
13. Gotfried MH. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Clin. Ther. 22(1), 2-14 (2000).
14. Doern GV, Brueggemann AB, Pierce G et al. Prevalence of antimicrobial resistance among 723 out-patient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40, 1208-1213 (1996).
15. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J. Chemother. 11, 11-27 (1999).
16. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37, 385-398 (1999).
17. Rodvold KA, Gotfried MH, Danziger LH, Sorvi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41, 1399-1402 (1997).
18. Patel KB, Xuan D, Tessier PR et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40 (10), 2375-2379 (1996).
19. Retsema JA, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur. J. Clin. Micro. Infect. Dis. 10, 834-842 (1991).
20. Palmer R, Shortridge D, Devcich K et al. Macrolide resistance prevalence in S. pneumoniae: surveillance study reports vs. clinical trial efficacy. 6th International Conference on the Macrolides, Azalides, Streptogramins Ketolides and Oxazolidinones 2002; January 23-26 Bologna (Abstract no. 8.07).
21. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Int. Med. 106, 196-204 (1987).
22. Adler JL, Jannetti W, Schneider D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther. 22, 1410-1420 (2000).
23. Anzueto A, Fisher CL, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 23, 72-86 (2001).
24. Notario G, Nalepa P, Dobryniewska M et al. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: A double-blind, randomized, multicenter comparison of extended release vs. immediate release clarithromycin. Curr. Med. Res. Opin. (In Press).
25. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 163, 1730-1754 (2001).
26. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease Society of America. Clin. Infect. Dis. 31, 347-382 (2000).
27. Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 31, 383-421 (2000).
28. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160, 1399-1408 (2000).
29. File TM, Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults. Drugs 63, 181-205 (2003).
30. Bishai W. Current issues on resistance, treatment guidelines and the appropriate use of fluoroquinolones for respiratory tract infections. Clin. Ther. 24, 838-850 (2002).
31. Gotfried MH, Dattani D, Riffer E et al. A controlled, double-blind, multi-center study comparing clarithromycin extended release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin. Ther. 24, 736-751 (2002).
32. Sokol WN, Sullivan JG, Acampora MD et al. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. Clin. Ther. 24, 605-615 (2002).
33. FDA guidance for industry. CAP-developing antimicrobial drugs for treatment. Available at: www.fda.gov/cder/guidance/2570dft.pdf Accessed February (2003).
34. Murray JJ, Solomon E, McCluskey D et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther. 22, 1421-1432 (2000).
35. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharmacokinet. 11, 137-152 (1992).
36. Guay DR, Gustavson LE, Devcich KJ et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23, 566-577 (2001).
37. Stratton CW. Get a handle on resistance before it gets a handle on you: the PROTEKT US Surveillance Study. Prospective Resistant Organism Tracking and Epidemiology for Ketolide Telithromycin. South Med. J. 94, 891-892 (2001).
38. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin. Infect Dis. 27, 764-770 (1998).
39. Labro MT. AntiInflammatory Activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 41, S37-46 (1998).
40. Kohyama T, Takizawa H, Kawasaki S et al. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob. Agents Chemother. 43, 907-911 (1999).
41. Culic O, Erakovic V, Parnham MJ. Antiinflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429, 209-229 (2001).
42. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-κB but not NFAT, through calcineurin-independent signaling in T-cells. Antimicrob. Agents Chemother. 43, 2678-2684 (1999).
43. Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nuclear factor-κ B and activator protein-1 activation in human brochial epithelial cells. Biochem. Biophys. Res. Commun. 267, 124-128 (2000).
44. Credito KL, Jacobs MR, Appelbaum PC. Activity of ABT-773 (a new ketolide) compared to 11 other drugs against H. influenzae by time-kill. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 17, 182 (2000).
45. Ichiyama T, Nishikawa M, Yoshitomi T. Clarithromycin Inhibits Nf-κ B Activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 45, 44-47 (2001).
46. Miyanohara T, Ushigai M, Matsune A, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblast. Laryngoscope 110, 126-131 (2000).
47. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Ped. Pulm. 31, 464-473 (2001).
48. Garey K, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 123, 261-265 (2003).
49. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother. 39, 1688-1690 (1995).
50. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 122, 213-218 (2002).
51. MacLeod CM, Hamid QA, Cameron L et al. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv. Ther. 18(2), 75-82 (2001).
52. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage, Am. J. Rhinology 14, 143-148 (2000).
53. Garey K, Rubinstein I, Gotfried MH et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118, 1826-1827 (2000).
54. Miyatake H, Taki F, Taniguchi H et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99, 670-673 (1991).
55. Amayasu H, Yoshida S, Ebana S et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol. 84, 594-598 (2000).
56. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and chlamydia pneumoniae in asthma effect of clarithromycin. Chest 121, 1782-1788 (2002).